Proton Beam Therapy Shows Promise in Reducing Ventricular Tachycardia Episodes

Recent findings from Mayo Clinic researchers highlight the potential of noninvasive proton beam therapy as a treatment option for patients with ventricular tachycardia (VT), a serious heart rhythm disorder. In a first-in-human early feasibility study, the therapy reduced VT episodes by nearly 80% among participants with limited treatment alternatives.

The results were shared at the Heart Rhythm Society conference and published in the Heart Rhythm Journal. The study involved seven patients with advanced heart disease who had not responded to conventional treatments like catheter ablation or antiarrhythmic medication. Following treatment with proton beams, the average number of VT episodes dropped from 7.2 to 1.5 per month. Remarkably, the therapy was administered in a single session and was well-tolerated, with no significant treatment-related side effects observed during a follow-up period of up to two years.

Dr Konstantinos Siontis, a cardiologist and the study's lead investigator, stated, "These patients with challenging arrhythmias often run out of treatment options. We're seeing that a completely noninvasive approach may significantly reduce episodes of ventricular tachycardia."

Cardiac radioablation, which targets areas of the heart generating abnormal electrical signals, has emerged as a promising approach. Proton beam therapy, due to its precision, reduces radiation exposure to surrounding healthy tissue, distinguishing it from other forms of radiation treatment.

Dr Kenneth Merrell, a radiation oncologist involved in the study, emphasized the precision of this approach, stating, "These findings are encouraging because they demonstrate that we can precisely target the heart tissue responsible for VT while minimizing radiation exposure to the rest of the heart."

While the therapy showed promise, some patients experienced severe heart failure complications requiring a heart transplant or resulting in death, indicating the advanced stage of their underlying disease. Dr Siontis notes the importance of continued research, "Our results support continued investigation of proton beam therapy in larger clinical trials. The goal is to better understand which patients may benefit most and to confirm long-term safety and effectiveness."

This study paves the way for further exploration into the use of proton therapy for cardiac conditions, demonstrating a novel potential treatment approach for patients with refractory ventricular tachycardia.